Salvat presents its innovations in ophthalmology, gastroenterology and self‑care at Infarma 2026

/in /by
  • Grupo Farmacéutico Salvat returns as an exhibitor at Infarma with the aim of demonstrating its strong commitment to the Pharmacy sector and strengthening the role of the pharmacist. To this end, this year the company is offering AI tools applied to the daily work of Community Pharmacy.
  • The laboratory is presenting the latest updates to its portfolio: from the renewal of the Relive® range within its Ophthalmology Unit with the launch of Relive® Confort Periocular, to its Consumer Health Care (CHC) flagships such as Cristalmina® and Urosens®, as well as the Gastroenterology area with MegaLevure®.

Tuesday, March 24, 2026. Grupo Farmacéutico Salvat, a laboratory specialized in the development of pharmaceutical technologies for health management, is once again participating in Infarma 2026, the leading European pharmacy event. As a market leader in self‑care, Salvat aims to reinforce its commitment to the pharmacy channel by presenting its latest innovations designed to promote healthier living in areas such as Ophthalmology, Gastroenterology and personal care.

The event, held this year at IFEMA Madrid on March 24, 25 and 26, has consolidated its position as a unique meeting point for pharmacy professionals, who attend to discover the latest industry trends, update their scientific knowledge and optimize their daily practice.

With this in mind, Salvat has designed a comprehensive proposal for the Congress that blends tradition and innovation. Under the slogan “The Salvat News: innovation worth sharing,” the company seeks to bring its current transformation phase closer to pharmacists, inviting them to learn about the Group’s more than seven decades of history and its strong in‑house production and innovation capabilities.

This commitment to evolution is especially reflected in the technological field. Under the theme “Good news: Salvat brings AI to the Pharmacy,” the company has also organized a series of sessions on practical Artificial Intelligence (AI) tools designed to improve the pharmacist’s daily workflow, enabling technology to support administrative tasks and free up more time for patient counseling.

In this context, Sergio Fernández Huertos, Consumer Healthcare and Channel Management Director at Salvat, highlights the company’s ambition at this event: “We come to Infarma with renewed ambition and full of good news about the company and the products that showcase our work. We want pharmacists to feel that Grupo Farmacéutico Salvat is their strategic ally in this new digital and healthcare landscape that drives us to keep evolving.”

New developments in Salvat’s portfolio

Innovation in eye care with the Relive® range

The Ophthalmology Unit is one of Salvat’s strategic pillars and, for this edition, the spotlight is on the Relive® range, designed to address dry eye and now featuring a renewed image to enhance visibility and accessibility. The line continues to grow with the launch of Relive® Confort Periocular, an innovative micellar lotion introduced at Infarma to showcase a new approach to periocular hygiene and care.

Leadership in Consumer Health Care with Cristalmina® and Urosens®

In the self‑care segment, Salvat is using Infarma to highlight the trajectory of Cristalmina®, Spain’s best‑known and leading antiseptic, which celebrates its 40th anniversary this year as an iconic, in‑house manufactured product. The Group is also reinforcing the relevance of Urosens® as a natural, trusted ally in the prevention of urinary discomfort.

Gastroenterology: MegaLevure® and microbiota balance

As a benchmark in the digestive health area, Salvat is also presenting important updates in the evolution of MegaLevure®. This product continues to consolidate its position as a key solution for pharmacists in restoring intestinal microbiota balance, reaffirming the scientific rigor the company applies across all its therapeutic areas.

Salvat Pharmaceutical Group surpasses €100 million in revenue and boosts EBITDA by 25% after launching its transformation process

/in /by
  • After Jordi Muntañola’s first year as CEO, the organization has accelerated its cultural and organizational transformation process, with a strong focus on strategic areas such as ophthalmology and otorhinolaryngology.
  • The pharmaceutical company has achieved record results driven by growth in both the Pharma and CDMO divisions.
  • In 2025, the company secured strategic projects to continue strengthening its industrial capabilities, positioning itself as a leading manufacturer of sterile Blow-Fill-Seal (BFS) technology in the European market.

Barcelona, March 18, 2026. Grupo Farmacéutico Salvat has presented its financial results for fiscal year 2025, a year marked by the beginning of a strategic transformation aimed at driving profitable growth, professionalization, and a strong commitment to talent.

In 2025, Salvat reached total net revenues of 100.3 million euros, representing a 10.3% increase compared to the previous year. This solid performance was reflected exceptionally in operating profitability: total EBITDA grew by 24.6%, reaching 17.2 million euros.

The pharmaceutical business played a key role in the group’s growth, generating revenues of 93.8 million euros, an increase of 9.4%. The Spanish market remained the main growth engine with 69.8 million euros, while the International division grew by 10%.

The company’s business model also includes top-tier industrial capabilities. In 2025, the contract development and manufacturing division (CDMO) strengthened its position as one of Salvat’s main growth drivers, reaching revenues of 6.59 million euros, a 24.4% increase compared to 2024.

“Salvat has entered a new phase, and it has done so with historic results,” said Jordi Muntañola, CEO of Salvat. “Surpassing 100 million euros in revenue for the first time is a milestone that reflects the strength of our business model and the work of the entire team. We are building a more agile, strategic organization, prepared to compete at the highest international standards.”

Innovation and industrial capabilities

Innovation remains one of Salvat’s strategic pillars. In 2025, the company invested 5 million euros in proprietary R&D—5% of its sales—with the goal of strengthening its technological platforms and developing differentiated therapeutic solutions in ophthalmology and otorhinolaryngology.

During the year, Salvat also reinforced its international expansion with key milestones such as FDA approval of its otic treatments, including clotrimazole, for the United States, as well as authorization of the ciprofloxacin and fluocinolone acetonide combination for China. The company also secured strategic projects to further enhance its industrial capacity and position itself as a European benchmark in sterile manufacturing using Blow-Fill-Seal (BFS) technology at its Pharmaloop plant in Madrid.

Social impact and talent: Commitment to purpose

Salvat’s transformation process has also been reflected in its culture and human capital. The company now has a team of more than 500 employees and, following the appointment of Jordi Muntañola as CEO one year ago, has strengthened its structure with key hires in 2025 to lead strategic functions.

True to its purpose of contributing to a healthier and happier life, the group reinvests part of its profits to support scientific research projects, promote artistic and musical talent, and assist vulnerable communities through the Salvat Foundation.

SALVAT receives FDA approval for Clotic®, an innovative treatment for otomycosis with Orphan Drug Designation

/in , , /by
  • This new drug, formulated with clotrimazole as its active pharmaceutical ingredient, addresses a significant unmet clinical need in the management of otomycosis. It offers a highly effective therapeutic option for alleviating the hallmark symptoms of fungal infections affecting the external auditory canal.
  • Following its commercial rollout in Spain in September 2025, it is scheduled for launch in the U.S. market in early 2026.

    • Salvat Pharmaceutical Group has announced that the U.S. Food and Drug Administration (FDA) has approved 1% otic clotrimazole, the first targeted treatment for otomycosis, for commercialization in the United States.

    Developed entirely by Salvat, the product will be manufactured at the company’s Pharmaloop facility in Alcalá de Henares (Madrid), which recently received FDA approval. This new approval marks a major scientific and industrial milestone for both Salvat and the broader Spanish pharmaceutical industry. It follows two prior FDA approvals for Salvat products and reinforces Pharmaloop’s international standing as a leading site for the production of sterile single-dose medicines using Blow-Fill-Seal (BFS) technology.

    This new pharmaceutical product is presented as a sterile, single-dose otic solution designed to ensure optimal safety and dosing precision at the time of administration. Its innovative anhydrous formulation, containing 1% clotrimazole, enhances antifungal efficacy while maintaining an excellent safety and tolerability profile. Developed to address an unmet clinical need, it represents a significant therapeutic advancement in the management of otomycosis. The product’s clinical performance was validated through Phase III clinical trials conducted across Europe, the United States, and Mexico.

    “Otomycosis continues to pose a clinical challenge due to the lack of specific therapies and its high recurrence rate. In this context, 1% otic clotrimazole stands out as the treatment of choice, combining robust antifungal efficacy with an excellent safety profile” said Dr. Serafín Sánchez, President of the Spanish Society of Otolaryngology and Head and Neck Surgery (SEORL-CCC).

    “This FDA approval underscores our commitment to scientific innovation and consolidates Salvat’s leadership in otology, while supporting our ongoing international expansion,” added Jordi Muntañola, CEO of Salvat Pharmaceutical Group.

    The product is scheduled to be launched in the U.S. market in early 2026, following its commercial introduction in Spain and other European countries on September 1, 2025. The company will officially present the medicine in the Spanish market at the end of October during the 76th Congress of the Spanish Society of Otolaryngology and Head and Neck Surgery (SEORL-CCC), reaffirming its close relationship with the scientific community and its dedication to advancing clinical practice in ENT disorders.

Jordi Muntañola, new CEO of the Salvat Pharmaceutical Group

/in , , /by

A new phase begins for the Salvat Pharmaceutical Group, comprised of Laboratorios Salvat, Pharmaloop, and Salvat USA. The pharmaceutical company has appointed Jordi Muntañola as the new Chief Executive Officer (CEO). With an international leadership profile and over 20 years of experience in the pharmaceutical industry, Muntañola takes on the role with the aim of consolidating the company’s global expansion and strengthening its presence in key markets.

Born in Barcelona in 1978, Muntañola holds a PhD in Molecular Biology from the University of Navarra and an MBA from ESADE. Throughout his career, he has worked at companies like Laboratorios Esteve, Grupo Werfen, and Esaote, leading teams in R&D, corporate strategy, operations, business development, and transformation office. Recently, he held the position of Chief Commercial Officer (CCO) for the global pharmaceutical activity at Laboratorios Esteve, where he led its international expansion by accelerating profitable growth, developing high-performance teams, and expanding presence in key markets such as Europe, the United States, and China. Additionally, Muntañola has extensive experience in M&A, noted for his work in business development.

Innovation and International Expansion as Strategic Pillars

Muntañola’s appointment is part of Salvat’s strategic plan to accelerate its global growth and continue its commitment to innovation in the pharmaceutical sector. “Salvat Group is a company with great potential, and it is an honor to lead the company in this new phase. Together, we will strengthen our global position and continue bringing innovation to our patients,” stated Muntañola.

Jordi Muntañola replaces Alberto Bueno, who concludes his tenure leading the company after 13 years. Under his direction, Salvat consolidated its growth and strengthened its production capacity, highlighting key projects such as the Pharmaloop plant, enabling Salvat to become the first Spanish laboratory authorized by the FDA to manufacture sterile drugs using BFS technology.

Salvat becomes the first Spanish pharmaceutical company to receive FDA approval for sterile drug manufacturing using BFS technology

/in , , /by
  • The pharmaceutical company Salvat has received FDA approval to manufacture Otovel, an ear drop solution for the treatment of acute otitis media, at its Pharmaloop facility in Alcalá de Henares for distribution in the U.S. market.
  • In addition to Otovel, Salvat is expected to produce three more products from its otolaryngology and ophthalmology lines for the U.S. market in the coming months.
  • The launch of Pharmaloop and the FDA authorization have led to the creation of more than 150 highly skilled jobs and an investment of over €80 million.
  • This new milestone further consolidates Salvat’s position as a leader in ophthalmology and otolaryngology, with four lines of single-dose products and one of sterile multi-dose products.

Salvat, an international pharmaceutical company and manufacturer of products such as Cristalmina, Relive, Otovel, Tebarat, and Cetraxal, is significantly expanding its presence in the global market. The Pharmaloop plant, located in Alcalá de Henares (Madrid), has become the first facility in Spain to receive FDA authorization for the manufacturing of sterile products using BFS technology for the U.S. market. The approval from the U.S. Food and Drug Administration (FDA) covers the production of Otovel, an ear drop solution for the treatment of acute otitis media.

Pharmaloop is also working towards obtaining FDA approval to manufacture three additional solutions: Cetraxal, for the treatment of acute external otitis; Clotrimazole, an antifungal solution for the treatment of otomycosis; and Clobetasol, a corticosteroid for post-surgical ophthalmic treatment. These solutions will be produced in Spain and are expected to be shipped to the U.S. in 2025.

With this manufacturing authorization, Salvat Laboratories not only completes its business chain but also opens the door to manufacturing for third-party companies interested in distributing BFS technology-based solutions in the U.S. market.

A State-of-the-Art Facility

Designed from the outset to meet FDA standards, the construction of the plant in 2019 involved an investment of €65 million. With the addition of personnel, energy activation, and machinery setup, the total investment has reached €80 million.

In 2023, Pharmaloop generated more than 100 jobs, and today, it has created over 150. Given the high-tech nature of the plant, these positions are filled by highly qualified professionals, including pharmacists, technicians, mechanics, and engineers, all trained to operate the sophisticated technology at Pharmaloop.

Focus on Ophthalmology and Otolaryngology

This latest milestone consolidates Salvat Laboratories as a leading player in the fields of ophthalmology and otolaryngology, with four lines of single-dose sterile products and one line of multi-dose products.

The company already offers several BFS technology-based solutions in European markets, targeting conditions such as glaucoma, conjunctivitis, post-surgical ophthalmic care, external otitis, acute otitis media, and allergic rhinitis, among others.

Alberto Bueno, CEO of Salvat Laboratories, highlighted the importance of the FDA approval: “We believe this is a key milestone in our international strategy. Having FDA clearance to manufacture certain sterile medications at Pharmaloop for the U.S. market gives third parties the confidence to rely on our facility. This not only boosts our business potential but also enhances our ability to provide the public with sophisticated solutions for their health needs,” he explained.

Laboratorios Salvat strengthens its commitment to those affected by glaucoma by meeting their specific needs

/in , , , /by
  • The pharmaceutical company and the Glaucoma Association for People Affected and Families (AGAF) in collaboration and endorsed by the Spanish Glaucoma Society will publish the book ‘The 101 doubts about Glaucoma that you always wanted to know and did not dare to ask’.
  • The laboratory thus reaffirms its presence in the field of ophthalmology to benefit families, professionals and patients involved in the management of the disease.
  • Around 60 million people worldwide suffer from this eye ailment. 7.8 million of these cases are Europe-based, with a prevalence of 2.51% in the continent.

    • Salvat, an international pharmaceutical laboratory, reaffirms its presence and commitment in the field of ophthalmology to benefit families, professionals and patients involved in the treatment of glaucoma. On the occasion of the International Day of this disease, the pharmaceutical company announces the forthcoming publication of the book ‘The 101 doubts about Glaucoma that you always wanted to know and did not dare to ask’ in collaboration with the Glaucoma Association for People Affected and Relatives (AGAF) and the Spanish Glaucoma Society (SEG). Thus, both are committed to offering more effective support by identifying the specific needs of people suffering from Glaucoma.

    According to the study ‘Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future’, around 60 million people worldwide are affected by primary open-angle glaucoma (POAG), with 7.8 million of those cases being Europe-based. The prevalence of the disease this continent is of 2.51%. Also, by, 2040, it is expected that more than 110 million around the world will suffer from glaucoma. It has been proven that early detection of it is essential to prevent its effects and treat it appropriately. If not, the condition may progress as a silent disease.

    ‘The 101 doubts about Glaucoma that you always wanted to know and did not dare to ask’ is part of the commitment of Salvat, AGAF and SEG to improve the quality of life of people affected by glaucoma. The book will resolve a whole series of questions of people affected by the disease that, for various reasons, they find difficult to convey to doctors. These questions have been answered thanks to the different health professionals provided by the Spanish Glaucoma Society (SEG), which has also endorsed the content of the texts. The book will have different thematic blocks: daily life, technical information about the disease, treatments and interventions, psychological aspects and improvement of disease control.

    Alberto Bueno, CEO of Laboratorios Salvat, highlights the company’s efforts to assist all those who deal with glaucoma. “As a company operating in the healthcare field, we are very clear that our work must go beyond the development of pharmaceutical products. Both professionals around the world who work on the treatment of Glaucoma and patients suffering from the disease need their necessities to be addressed, which, unfortunately, can go unnoticed. That is why we intend to continue listening to them in order to be able to work on new dissemination materials that can be useful to as many people as possible,” he explains.

    For his part, Joaquín María Carratalá, president of AGAF, stresses the help that the publication represents. “For the Glaucoma Association for Patients and Relatives, this book is the answer to many doubts that patients have raised throughout the 18 years that AGAF has been having. Addressing all these issues, giving explanations from experts and at the forefront of care for people with glaucoma, is a reference for resolving these issues. Glaucoma patients, from the moment they are diagnosed, pose problems that there is not always time to respond to in medical consultations. They also have doubts about issues that are not properly medical. For this reason, in this book we wanted to encompass all these concerns, something that for our association is a very important help when it comes to dealing with the disease. Hence our thanks to all the parties who have made this publication possible together with us.”

    Dr. Francisco J. Muñoz Negrete, president of the SEG , adds: “Due to the enormous burden of care, it is impossible to provide the patient with all the information and resolve all the doubts that arise about glaucoma and its treatment. Thanks to materials such as this manual, it will be possible to prevent those affected by the disease from resorting to incomplete, poorly verified or outright false information found on the web. Having access to science-based answers will undoubtedly improve our understanding of glaucoma. In addition, it will help the patient to improve their lifestyle habits in order to better control the disease.”

Salvat Laboratories initiates a pioneering pediatric study in Europe with its innovative drug SVT-15473, for the treatment of inflammation and pain following ocular surgery

/in , , /by

  • Phase III clinical trials conducted in adults confirm the efficacy and excellent safety profile of SVT-15473 ophthalmic clobetasol, formulated with IMPACT-SVT® patented nanoemulsion technology, for the treatment of inflammation and pain following ocular surgery.

  • This is the first clinical study conducted in Europe in pediatric patients with a topical ophthalmic corticosteroid.

  • With the new study, which is being carried out in six Spanish hospitals, its safety in pediatric patients aged 0 to 3 years is expected to be also demonstrated.

  • With this project, which has involved a total investment of over 20 million euros, Salvat Laboratories takes another step in its strategy to establish itself as a key international player in the field of ophthalmology.

Salvat, an international laboratory that develops, manufactures, and markets products such as Cristalmina®, Gama Relive®, Tebarat®, and Cetraxal® Plus, has initiated a new study with SVT-15473 clobetasol, the first ocular corticosteroid formulated with IMPACT-SVT® patented nanoemulsion technology, to treat inflammation and pain in patients undergoing ocular surgery. In this case, the trial will include children aged 0 to 3 years with cataracts, aiming to demonstrate the drug’s safety in this population as well.

Cataracts in pediatric patients can be congenital or acquired as part of certain diseases. Overall, the incidence of pediatric cataracts ranges from 1 to 5 cases per 10,000 individuals.

The new study, which is the first to be conducted in Europe with topical corticosteroids in this pathology and population, will include 60 cases randomly divided into two equal groups. One group will be treated with SVT-15473, and the other, as a control group, with Prednisolone. The study will take place in six Spanish hospitals, with coordination led by Dr. Marta Morales, Head of the Ophthalmology Department at Hospital Sant Joan de Déu in Barcelona. The participating hospitals include Vall d’Hebron Hospital and Germans Trias i Pujol Hospital, both in Barcelona, La Paz Hospital in Madrid, Cruces Hospital in Bilbao, and Miguel Servet Hospital in Zaragoza. Currently, there are already 4 patients included and treated.

The conduct of this new study was agreed upon with the Food and Drug Administration (FDA), as part of the approval process that has already been initiated, based on the results of clinical trials involving 400 adult patients from 50 hospitals in the United States. These trials demonstrated the effectiveness and safety of SVT-15473 in treating inflammation and ocular pain following cataract surgery.

This new study, which aims to demonstrate the safety of SVT-15473 in patients aged 0 to 3 years, is complementary and does not interfere with the ongoing approval process, which is expected to conclude soon. “Once we have completed this study in the pediatric population, the indication could be expanded to include this age group, allowing the use of SVT-15473 clobetasol in any patient, regardless of their age,” explains Enrique Jiménez, Medical Director of Salvat Laboratories.

Innovation in the Industry

Salvat has developed IMPACT-SVT®, a patented nanoemulsion technology (emulsion with nanometer-sized droplets) for drug administration, promoting its penetration and accelerating the onset of its action, while providing excellent ocular comfort. IMPACT-SVT® has enabled the development of SVT-15473 using clobetasol, a “superpotent” corticosteroid that has never been used in the form of eye drops before.

Manufactured with BFS (Blow-Fill-Seal) technology, a sterile, advanced, and automated single-dose vial manufacturing system, SVT-15473 will be produced in the manufacturing line of Salvat USA Inc. in Miami, Florida, and in Pharmaloop S.L., Salvat’s facility in Alcalá de Henares, Madrid.

With this project, which has involved a total investment of over 20 million euros, Salvat Laboratories takes another step in its strategy to establish itself as a key international player in the field of ophthalmology.

Salvat Laboratories presented Phase III clinical trials results of Clobetasol Nanoemulsion for treating inflammation and pain after ocular surgery at the 2023 ARVO Annual Meeting

/in , , /by

Salvat Laboratories, the international pharmaceutical company focused on the development, manufacturing, and commercialization of ophthalmology treatments, announced the results of phase III clinical trials of its most potent ophthalmic corticosteroid in the global ophthalmology market at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held from 23-27 April 2023 in New Orleans. Studies’ global coordinator, Dr. Andrew Schwartz (Fifth Avenue Eye Associates, NYC), presented a poster outlining the SVT-15473 clobetasol 0.05% ophthalmic nanoemulsion phase III clinical trial results for the treatment of inflammation and pain post-ocular surgery.

The presentation includes the pooled data of two successful phase III clinical trials of clobetasol, which were conducted between 2020 and 2021, testing more than 400 patients in over 40 specialized centers in the United States. The trials demonstrated the efficacy and safety of this innovative approach, with clobetasol proving effective in reducing inflammation and pain in post-ocular surgery patients. Read more about the clinical trials here.

Salvat Laboratories has developed IMPACT-SVT®, a patented nanoemulsion drug delivery technology that improves drug penetration and bio-adhesion, providing excellent comfort. IMPACT-SVT® made it possible to develop SVT-15473 using clobetasol, a “superpotent” corticosteroid that had never been used before as eye drops. In addition to its efficacy and safety, clinical trials have shown that it has very low impact on intraocular pressure, unlike many other corticosteroids.

The exclusive nanoemulsion formulation (emulsion with drops of nanometric size) offers superior advantages over other established alternatives that are readily available, including better coverage of the ocular surface, more effective absorption, and no blurred vision or discomfort after application. After a standard 14-day course of treatment, the therapy has proven to have no rebound effect in the following 2 weeks, hence not requiring a gradual decrease in dosage towards the end of treatment.

Designed with Blow-Fill-Seal technology, an advanced, sterile, and automated single-dose vials manufacturing system, the new drug will be produced on the manufacturing line of Salvat USA Inc. in Miami (Florida), and at Salvat’s manufacturing site Pharmaloop S.L. in Alcala de Henares (Madrid).

The new drug is currently being reviewed by the US Food and Drug Administration (FDA), with approval expected in summer 2023. The submission of the NDA to the FDA is a significant step in the company’s strategy to position itself as one of the main players in the field of ophthalmology worldwide in the coming years.

Salvat Laboratories has invested over 20 million euros into this project, reinforcing its ophthalmology line as one of its main areas of research and development, aiming to improve people’s quality of life through innovation and the development of medicines and healthcare products with high-added value.

Salvat Laboratory submits application to the U.S. FDA for approval of Clotrimazole, a pioneering drug for the treatment of otomycosis

/in , , /by

  • The new drug will be the only one on the market in the United States and Europe specifically formulated and indicated for the topical treatment of fungal otitis externa.
  • Salvat has invested 22 million euros in this project with which reinforces its position as a leading laboratory in the field of otology at an international level.

Salvat, an international pharmaceutical company focused on the development, manufacturing and commercialization through partners worldwide of products such as Otovel and Cetraxal, has submitted the new drug application (NDA) for Clotrimazole to the FDA, the new treatment for fungal otitis externa.

The company thus begins the procedures to launch the new drug in the American market, where it is expected to be available in summer 2023.

For Alberto Bueno, CEO of Salvat, “this project is a reflection of the firm commitment we have made to R+D in the area of otology, and reinforces our leadership position in this therapeutic area, without losing focus on other areas of strategic growth for Salvat”.

Single and cutting-edge drug in otology

Salvat’s Clotrimazole represents a breakthrough in the treatment of this type of otitis externa since it will be the first and only existing drug in the United States and Europe specifically indicated to treat this pathology. While there are other medications or formulations on the market that can help managing the symptoms of this condition, Salvat’s bet is the only one focused on effectively treating otomycosis.

Salvat has specifically formulated Clotrimazole for otic use in the form of single-dose vials, making it easier for patients to use. This format also ensures the sterility of the product and, by containing the necessary amount of active ingredient, also warrants the correct use of the drug.

Years of research with exceptionally good results

The new drug has undergone two demanding clinical trials to evaluate its efficacy and safety. The trials have been conducted over 3 years in more than 400 adult patients affected by otomycosis, from hospitals in the United States, Mexico, and Europe.

Both studies have concluded with very positive results that confirm the efficacy and safety of the new drug for the eradication of the fungus that causes otomycosis and the associated clinical symptoms (pain, itching, feeling of fullness and hearing loss).

Investment and manufacturing

Since 2019, Salvat has invested more than 22 million euros in the development of this formulation of Clotrimazole, whose manufacture will be carried out in the plants of Salvat USA Inc. in Tamarac (Florida) and in the plant of Pharmaloop, S.L. in Alcalá de Henares (Madrid). Both companies are subsidiaries of Laboratorios Salvat S.A.

Salvat, pioneer in Otolaryngology

Salvat is one of the top pharmaceutical companies in developing and commercializing innovative otology products. Also, Salvat is the first to develop and commercialize otic drug products in single-dose vials worldwide. Otolaryngologists recognize Salvat as the number 1 company in the development of treatments for otology. This new drug for the treatment of otomycosis confirms Salvat’s commitment to this medical specialty and the company’s willingness to strengthen its leadership in the treatment of ear diseases.

Salvat Laboratory obtains the qualification “Excellent” in the PROFARMA program

/in /by

  • Salvat is one of the top-rated pharmaceutical companies that has achieved the best rating in the PROFARMA program, among the 49 evaluated by the Ministry of Industry, Trade and Tourism.
  • The PROFARMA Plan seeks to increase the competitiveness of the industry through the modernization of the sector and the enhancement of activities that provide greater added value.
  • The company has won the award thanks to the continuous research and development of innovative medicines with high added value in ophthalmology, otology and in the treatment of bone fractures.

Salvat, an international pharmaceutical company focused on the development, manufacturing and commercialization through partners worldwide of products such as Otovel, Cetraxal, Monolitum Flas, Relive, Tebarat and Cristalmina, has obtained the rating of “Excellent” by the Technical Committee of the Program for the Promotion of Competitiveness in the Pharmaceutical Industry (PROFARMA), which has evaluated 49 applications from pharmaceutical companies.

The program, managed by the Ministry of Industry, Trade and Tourism, classifies pharmaceutical firms into groups and categories according to their excellence in various industrial, economic and research, development and innovation fields. In relation to their standards, the 49 applicant firms have been rated as “Excellent”, “Very Good”, “Good”, or “Acceptable”.

The main objective of the PROFARMA plan is to promote the competitiveness of the pharmaceutical industry in Spain, either by promoting activities that provide greater added value or by promoting R&D through investment in new facilities and technologies.

“This mention is a reflection of the firm commitment we have made to R&D in the different fields we explore, such as otolaryngology, ophthalmology or bone fractures, and reinforces our leadership position in these therapeutic areas”, explains Alberto Bueno, CEO of Salvat.

Innovative actor in different branches of medicine

Research and innovation are in the DNA of the company, which has made relevant contributions in the therapeutic advancement of various pathologies. In the field of ophthalmology, in addition to the development of an innovative ocular corticosteroid to treat inflammation and pain after cataract surgery, Salvat is working on four more projects such as glaucoma, dry eye, diabetic retinopathy and blepharitis.

The pharmaceutical company is also positioned as the number 1 company in the development of treatments for otology after the development of the first drug with specific indication for otomycosis. Additionally, Salvat has been working on a pioneering project based on pre-differentiated mesenchymal stem cells aimed at treating patients with bone consolidation problems after a fracture (atrophic pseudoarthrosis).

All these contributions have earned Salvat the recognition of the Technical Committee of the Program for the Promotion of Competitiveness in the Pharmaceutical Industry in this last call.